AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

Cancer Research

Volumn 65, Issue 10, 2005, Pages 4389-4400

  Wedge, Stephen R ^a   Kendrew, Jane ^a   Hennequin, Laurent F ^a   Valentine, Paula J ^a   Barry, Simon T ^a   Brave, Sandra R ^a   Smith, Neil R ^a   James, Neil H ^a   Dukes, Michael ^a   Curwen, Jon O ^a   Chester, Rosemary ^a   Jackson, Janet A ^a   Boffey, Sarah J ^a   Kilburn, Lyndsey L ^a   Barnett, Sharon ^a   Richmond, Graham H P ^a   Wadsworth, Peter F ^a   Walker, Mike ^a   Bigley, Alison L ^a   Taylor, Sian T ^a   Cooper, Lee ^a   Beck, Sarah ^a   Jürgensmeier, Juliane M ^a   Ogilvie, Donald J ^a   more..

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 4 [(4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY] 6 METHOXY 7 [3 (PYRROLIDIN 1 YL)PROPOXY]QUINAZOLINE; ADENOSINE TRIPHOSPHATE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC DRUG ADMINISTRATION; COCULTURE; CONTROLLED STUDY; CORPUS LUTEUM; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; FIBROBLAST; HISTOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG TUMOR; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BONE DEVELOPMENT; CELL PROLIFERATION; CORPUS LUTEUM; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; MICE; NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEINS; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20144370978     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4409     Document Type: Article

References (67)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
2. Rousseau S, Houle F, Huot J. Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med 2000;10:321-7.
3. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (Washington DC) 1989;246:1309-12.
4. Lamoreaux WJ, Fitzgerald ME, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998;55:29-42.
5. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergio A, Perruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am J Pathol 1996;149:293-305.
6. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularisation by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72.
7. Koolwijk P, Peters E, van der Vecht B, et al. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis 2001;4:53-60.
8. Gerber H-P, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-43.
9. Benjamin LE, Memo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591-8.
10. Bates DO, Heald RI, Curry FE, Williams B. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol (Lond) 2001;533:263-72.
11. Rak J, Mitsuhashi L, Bayo L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumour angiogenesis. Cancer Res 1995;55:4575-80.
12. Mukhopadhyay D, Knebelmann B, Cohen HT, Anath S, Sukhatme VP. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 1997;17:5629-39.
13. Zhou YZ, Xiong YX, Wu XT, et al. Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol 2004;10:3225-9.
14. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci U S A 1995;92:768-72.
15. Tse V, Xu L, Yung YC, et al. The temporal-spatial expression of VEGF, angiopoietins-1 and -2, and Tie-2 during tumor angiogenesis and their functional correlation with tumor neovascular architecture. Neurol Res 2003;25:729-38.
16. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Crystal structure at 1.7 Å resolution of VTGF in complex with domain 2 of the Flt-1 receptor. Cell 1997;91:695-704.
17. Lu D, Kussie P, Pytowski B, et al. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing KDR-antibodies. J Biol Chem 2000;275:14321-30.
18. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinase. EMBO J 1999;18:363-74.
19. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signalling properties of Flt-1 and KDR: a reassessment using novel highly receptor-specific VEGF mutants. J Biol Chem 2001;244:3222-30.
20. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase-C dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221-30.
21. Rousseau S, Houle F, Kotanides H, et al. Vascular endothelial growth factor (VEGF)-driven actin-based motilityis mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/ p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 2000;275:10661-72.
22. Carmeliet P, Lampugnani MG, Moons L, et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999;98:147-57.
23. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
24. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
25. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
26. Beebe JS, Jani JP, Knauth E, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003;63:7301-9.
27. Sepp-Lorenzino L, Rands E, Mao X, et al. A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. Cancer Res 2004;64:751-6.
28. Hennequin LF, Thomas AP, Johnstone C, et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999;42:5369-89.
29. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
30. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000;62:970-5.
31. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000;59:368-76.
32. Zeng H, Sanyal S, Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 2001;276:32714-9.
33. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt-1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269:26988-95.
34. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000;275:16986-92.
35. Hillman NJ, Whittles CE, Pocock TM, Williams B, Bates DO. Differential effects of vascular endothelial growth factor-C and placental growth factor-1 on the hydraulic conductivity of frog mesenteric capillaries. J Vasc Res 2001;38:176-86.
36. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 1998;95:9349-54.
37. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43.
38. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004;5:74-80.
39. Onogawa S, Kitadai Y, Tanaka S, Kuwai T, Kimura S, Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004;95:32-9.
40. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 2003;97:457-64.
41. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
42. Shimizu K, Kubo H, Yamaguchi K, et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 2004;95:328-33.
43. Alam A, Herault J-P, Barron P, et al. Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun 2004;324:909-15.
44. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21.
45. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukaemia, and identification of an internal tandem duplication. Haematologica 2004;89:920-5.
46. Horner A, Bishop NJ, Bord S, et al. Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage. J Anat 1999;194:519-24.
47. Petersen W, Tsokos M, Pufe T. Expression of VEGF121 and VEGF165 in hypertrophic chondrocytes of the human growth plate and epiphyseal cartilage. J Anat 2002;201:153-7.
48. Nakagawa M, Kaneda T, Arakawa T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEES Lett 2000;473:161-4.
49. Mayr-Wohlfart U, Waltenberger J, Hausser H, et al. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002;30:472-747.
50. Midy V, Plouet J. Vasculotropin/vascular endothelial growth factor induced differentiation in cultured osteoblasts. Biochem Biophys Res Commun 1994;199:380-6.
51. Zelzer E, Mamluk R, Ferrara N, Johnson RS, Schipani E, Olsen BR. VEGFA is necessary for chondrocyte survival during bone development. Development 2004; 131:2161-71.
52. Gerber H-P, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nature Med 1999;5:623-8.
53. Haigh JJ, Gerber H-P, Ferrara N, Wagner EF. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 2000;127:1445-53.
54. Modlich U, Kaup FJ, Augustin HG. Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab Invest 1996; 74:771-80.
55. Ferrara N, Chen H, Davis-Smyth T, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998;4:336-40.
56. Zimmermann RC, Xiao E, Bohlen P, Ferin M. Administration of antivascular endothelial growth factor receptor-2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. Endocrinology 2002;143:2496-502.
57. Ryan AM, Eppler DB, Hagler KE, et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27:78-86.
58. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
59. Kiessling F, Farhan N, Lichy MP, et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004;6:213-23.
60. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70.
61. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
62. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
63. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity on VEGF-C. EMBO J 1997;16:3898-911.
64. Jia H, Bagherzadeh A, Bicknell R, Duchen MH, Liu D, Zachary I. Vascular endothelial growth factor (WGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem 2004;279:36148-57.
65. Koolwijk P, Peters E, van der Vecht B, et al. Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro. Angiogenesis 2001;4:53-60.
66. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
67. Medinger M, Mross K, Zirrgiebel U, et al. Phase I dose escalation study of the highly potent XEGF receptor tyrosine kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases. Proc Am Soc Clin Oncol 2004;23:208.